3 December 2014
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
Director / PDMR shareholding
Dechra Pharmaceuticals PLC has been notified that on 2 December 2014 Zoe Goulding, a PDMR of the Company, exercised 984 options over ordinary shares in the Company, granted to her on 17 October 2011 pursuant to the SAYE Scheme at an exercise price of £3.6554 each.
Following this acquisition, Zoe Goulding's beneficial interest in the Company is 20,545 shares (0.023% of the current issued share capital).
For further information, please contact:
Melanie Hall, Assistant Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.